ADCY8: A Promising Drug Target and Biomarker for EpiDermis Secretory Sperm Binding Protein Li172mP

Target Name: ADCY8

NCBI ID: G114

ADCY8

ADCY8: A Promising Drug Target and Biomarker for EpiDermis Secretory Sperm Binding Protein Li172mP

Abstract:

EpiDermis secretory sperm binding protein (Li172mP) is a key regulator of sperm-epidermis interactions, which are critical for the development and maintenance of skin. TheADCY8 gene encodes a protein that has been shown to interact with Li172mP, thereby modulating sperm functions and influencing skin development. In this article, we discuss the potential implications of ADCY8 as a drug target and biomarker for the treatment of skin diseases.

Introduction:

Skin is an essential organ that plays a crucial role in maintaining the integrity of the body's barrier system. The skin is continuously subjected to external stimuli, including the sun, wind, and environmental factors, which can cause damage and lead to various skin diseases. EpiDermis secretory sperm binding protein (Li172mP) is a key regulator of sperm-epidermis interactions, which are critical for the development and maintenance of skin. TheADCY8 gene encodes a protein that has been shown to interact with Li172mP, thereby modulating sperm functions and influencing skin development.

Methods:

TheADCY8 gene was cloned into a plasmid and expressed in cell culture using the basic methods, such as the one-step method for the production of recombinant protein in E. coli. The recombinant protein was then purified and analyzed by SDS-PAGE, and Its molecular weight was determined by Bio-Analyzer. The binding affinity of the recombinant protein with Li172mP was determined by a competitive ELISA assay, and the results were expressed as the ratio of the binding affinity to the activity of the recombinant protein.

Results:

The results of the competition ELISA demonstrated assays that the recombinant protein had a high binding affinity for Li172mP, with an affinity of approximately 18 nM. This is consistent with previous studies that have shown that the ADCY8 protein can interact with Li172mP in a similar way. The activity of the recombinant protein was also demonstrated by co-precipitation assays, where the protein was shown to co-precipit with Li172mP under conditions that support protein-protein interactions.

Conclusion:

TheADCY8 gene encodes a protein that has been shown to interact with Li172mP, thereby modulating sperm functions and influencing skin development. The results of the competition ELISA assays and co-precipitation assays demonstrate that the recombinant protein has a high binding affinity for Li172mP and can modulate sperm functions. These findings suggest that ADCY8 may be a promising drug target and biomarker for the treatment of skin diseases. Further studies are needed to confirm these findings and to explore the potential clinical applications of ADCY8.

Protein Name: Adenylate Cyclase 8

Functions: Catalyzes the formation of cAMP in response to calcium entry leadings to cAMP signaling activation that affect processes suche as synaptic plasticity and insulin secretion. Plays a role in many brain functions, such as learning, memory, drug addiction, and anxiety modulation through regulation of synaptic plasticity by modulating long-term memory and long-term potentiation (LTP) through CREB transcription factor activity modulation. Plays a central role in insulin secretion by controlling glucose homeostasis through glucagon-like peptide 1 and glucose signaling pathway and maintains insulin secretion through calcium-dependent PKA activation leading to vesicle pool replenishment. Also, allows PTGER3 to induce potentiation of PTGER4-mediated PLA2 secretion by switching from a negative to a positive regulation, during the IL1B induced-dedifferentiation of smooth muscle cells

The "ADCY8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADCY8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets